Allogene Therapeutics (ALLO) News Today $2.17 -0.09 (-3.98%) Closing price 04:00 PM EasternExtended Trading$2.17 0.00 (0.00%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Vontobel Holding Ltd. Boosts Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Vontobel Holding Ltd. boosted its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 788.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 195,457 shares of the company's stock after purchasFebruary 21 at 3:12 AM | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Sees Unusually-High Trading Volume - Still a Buy?Allogene Therapeutics (NASDAQ:ALLO) Sees Unusually-High Trading Volume - Should You Buy?February 20 at 11:53 AM | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Shares Gap Up - Should You Buy?Allogene Therapeutics (NASDAQ:ALLO) Shares Gap Up - Here's What HappenedFebruary 19 at 9:53 PM | marketbeat.comBaird ‘encouraged’ by Allogene CAR-T therapy updateFebruary 18 at 7:21 PM | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)February 18 at 8:17 AM | markets.businessinsider.comAllogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal yearFebruary 17, 2025 | msn.comPartners Capital Investment Group LLP Trims Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Partners Capital Investment Group LLP reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 63.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,248 sharesFebruary 17, 2025 | marketbeat.comAllogene Therapeutics (ALLO) Gets a Buy from Piper SandlerFebruary 14, 2025 | markets.businessinsider.comWilliam Blair Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)February 14, 2025 | markets.businessinsider.comAllogene publishes data from ALPHA, ALPHA2 trials of cemacabtagene ansegedleucelFebruary 13, 2025 | markets.businessinsider.comAllogene reports promising results for CAR T therapy in lymphomaFebruary 13, 2025 | msn.comAllogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical OncologyFebruary 13, 2025 | globenewswire.comAllogene stock plunges to 52-week low at $1.33 amid steep annual declineFebruary 12, 2025 | msn.comabrdn plc Buys Shares of 364,382 Allogene Therapeutics, Inc. (NASDAQ:ALLO)abrdn plc purchased a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 364,382 shares of the company's stock, valued at approximately $776,000. abrdn plc owned 0February 11, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Earl Martin Douglas Sells 6,404 SharesFebruary 6, 2025 | insidertrades.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Moderate Buy" by AnalystsAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued aFebruary 6, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Sells $10,950.84 in StockAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Earl Martin Douglas sold 6,404 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $10,950.84. Following the transaction, the senior vice president now owns 587,848 shares in the company, valued at approximately $1,005,220.08. This trade represents a 1.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.February 5, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Sells $25,215.66 in StockAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) insider Timothy L. Moore sold 14,746 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total value of $25,215.66. Following the transaction, the insider now owns 250,713 shares in the company, valued at $428,719.23. This represents a 5.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.February 5, 2025 | marketbeat.comAllogene Therapeutics Announces Participation in February Investor ConferencesFebruary 4, 2025 | finance.yahoo.comAllogene stock hits 52-week low at $1.76 amid market challengesFebruary 3, 2025 | msn.comAllogene Therapeutics, Inc.: Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical OfficerJanuary 29, 2025 | finanznachrichten.deCanaccord Genuity Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)January 29, 2025 | markets.businessinsider.comFDA Clears Allogene's IND for CAR T Therapy in Autoimmune DiseasesJanuary 29, 2025 | msn.comAllogene Therapeutics executive to depart, consulting agreement plannedJanuary 29, 2025 | msn.comAllogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical OfficerJanuary 29, 2025 | finance.yahoo.comAllogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune DiseasesJanuary 28, 2025 | globenewswire.comInsider Selling: Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Sells 27,199 Shares of StockJanuary 24, 2025 | insidertrades.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Sells $48,414.22 in StockAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) EVP Zachary Roberts sold 27,199 shares of the company's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the sale, the executive vice president now directly owns 488,054 shares in the company, valued at $868,736.12. This represents a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.January 23, 2025 | marketbeat.comZacks Research Issues Pessimistic Estimate for ALLO EarningsAllogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Investment analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for Allogene Therapeutics in a note issued to investors on Thursday, January 9th. Zacks Research analyst R. Department now expects that the compJanuary 13, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and niJanuary 12, 2025 | marketbeat.comThis Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?January 3, 2025 | msn.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Holdings Boosted by Geode Capital Management LLCGeode Capital Management LLC grew its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 14.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,227,104 shares of the company's stJanuary 2, 2025 | marketbeat.comState Street Corp Sells 655,041 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)State Street Corp cut its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 8.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,013,083 shares of the company's stock after selling 655,041 shares durDecember 24, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by AnalystsAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve brokerages that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and nine have issuedDecember 18, 2024 | marketbeat.comAllogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 16, 2024 | globenewswire.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest UpdateAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 31,170,000 shares, a decrease of 11.1% from the November 15th total of 35,050,000 shares. Based on an average daily volume of 2,260,000 shares, the days-to-cover ratio is currently 13.8 days.December 15, 2024 | marketbeat.comAllogene acknowledges passing of founding board member David BondermanDecember 13, 2024 | markets.businessinsider.comAllogene Therapeutics Acknowledges the Passing of Founding Board Member David BondermanDecember 12, 2024 | globenewswire.comPiper Sandler Remains a Buy on Allogene Therapeutics (ALLO)December 11, 2024 | markets.businessinsider.comDeborah M. Messemer Sells 9,136 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) StockDecember 11, 2024 | insidertrades.com516,601 Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Acquired by Zacks Investment ManagementZacks Investment Management purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 516,601 shares of the company's stock, valued at approxDecember 10, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Director Franz B. Humer Sells 9,221 SharesDecember 10, 2024 | insidertrades.comFmr LLC Cuts Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Fmr LLC cut its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 3.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,026,956 shares of the company's stock afterDecember 6, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Down 5.4% in NovemberAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 35,050,000 shares, a drop of 5.4% from the October 31st total of 37,040,000 shares. Based on an average daily volume of 2,160,000 shares, the days-to-cover ratio is presently 16.2 days.December 3, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Vestal Point Capital LPVestal Point Capital LP lowered its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 31.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,500,000 shares ofNovember 29, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendatiNovember 23, 2024 | marketbeat.comCautious Hold Rating for Allogene Therapeutics Amid Promising Preclinical Data and Intense CompetitionNovember 21, 2024 | markets.businessinsider.comAllogene Therapeutics presents data for ALLO-329 in autoimmune diseaseNovember 19, 2024 | markets.businessinsider.comAllogene Therapeutics Announces Participation in December Investor ConferencesNovember 19, 2024 | globenewswire.comAllogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) ConvergenceNovember 18, 2024 | globenewswire.com Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLO Media Mentions By Week ALLO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLO News Sentiment▼0.400.60▲Average Medical News Sentiment ALLO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLO Articles This Week▼94▲ALLO Articles Average Week Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IOVA News Today PRAX News Today GLPG News Today WVE News Today APGE News Today EVO News Today IRON News Today ARQT News Today AMPH News Today IMCR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLO) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLO Stock Alerts